Latest news and press releases about Harvard Bioscience, Inc. (HBIO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Price
| Price | $7.97 |
| Market Cap | $36M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 4.86 |
| EV / EBITDA | -78.67 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -92.01% |
| Return on Invested Capital | 1.91% |
| Return on Assets | -13.65% |
| Gross Margin | 58.16% |
| Operating Margin | 1.17% |
| Net Margin | -11.86% |
Related companies: CLGN · COSM · FEMY · NCNA · NXGL · NXL · RVP
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of HBIO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks